Skip to content
Innovative Tech
Diseases
Health Policy
HTA
Data Analysis
Clinical Practice
Contributors
BACK TO MAIN SITE
A Cost-Effectiveness Analysis of Emicizumab Tre...
By
HEOR Staff Writer
April 17, 2024
Introduction: The Future of Haemophilia A Treatment When it comes to rare blood diseases, the introduction of Emicizumab, a bispecific monoclonal antibody, has been a significant milestone in the
Innovative Technology Policy: Simulation Modelling in Healthcare
Policy of Innovative Health Technology: Biobanks in Abu Dhabi
Digital Health: The Impact of Standardising DHI Terminology
Evaluating the Impact of Molnupiravir in COVID-19 Treatment
AI in Healthcare Value Creation and Competitive Advantage
Strategic Cost Implications of Medical Countermeasure Stockpiling
Evaluating the Cost-Effectiveness of Adebrelimab in ES-SCLC
Innovations in Surgery: Clinical and Economic Implications
The Cost-Effectiveness of GaitSmart Rehabilitation Programme
AI-Enhanced Speech Restoration for Aphasia Patients
Clinical Trials in Saudi Arabia: An Insight from PDC-CRO
Forecasting Multidimensional Poverty: South Africa’s Policy Design
« Previous
1
…
27
28
29
30
31
…
47
Next »